PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics... Show more
PRFX is the stock ticker for PRF Technologies Ltd., a small-cap Israeli innovation company listed on the Nasdaq. The business focuses on developing reformulated and sustained-release drug-delivery technologies while also building an AI-driven renewable-energy analytics platform. Investors follow PRFX primarily because of its lead pain-management candidate and its recent push to diversify into ophthalmology and clean-energy technology, which has broadened its long-term market position beyond a single pharmaceutical asset.
PRF Technologies Ltd. was incorporated in Israel in November 2007 and began trading on the Nasdaq in September 2020. Its principal executive offices are located in Tel Aviv, Israel. For most of its history the company operated as PainReform Ltd., a specialty pharmaceutical firm focused on reformulating established therapeutics. In January 2026, shareholders approved a corporate name change to PRF Technologies Ltd. to reflect an evolution into a diversified platform spanning specialty pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics.
The company's core product focus has historically been PRF-110, an oil-based, viscous solution based on the local anesthetic ropivacaine. PRF-110 is designed to be applied directly into a surgical wound to provide localized, extended postoperative analgesia without the use of opioids or non-steroidal anti-inflammatory drugs (NSAIDs). The company's business model is built on advancing this lead candidate through clinical development, with a goal of commercializing it as a pain-management option for surgical patients.
Over time, PRF Technologies has expanded into additional business segments. Through its majority-owned subsidiary LayerBio, the company entered the ophthalmology space with OcuRing-K, a sustained-release, bio-erodible implant designed to manage pain and inflammation following cataract surgery and intended to reduce or eliminate the need for post-surgical eye drops. Separately, the company's DeepSolar business unit develops AI-based analytics for utility-scale solar and energy-storage assets, including tools for solar forecasting and revenue optimization.
Because PRF Technologies remains a clinical-stage and early-commercialization company, it generates only minimal revenue and has historically reported operating losses, which is common for development-stage pharmaceutical firms. The company's primary revenue potential lies in the future commercialization of its product candidates and the growth of its energy-analytics platform. In competitive terms, PRF Technologies operates in crowded fields: postoperative pain management is served by both established extended-release local anesthetics and generic options, while the solar-analytics market includes a range of established software and data providers.
Investor attention around PRFX is tied to several long-term themes. First, the company's lead candidate, PRF-110, targets the large postoperative pain market, where a non-opioid, extended-release option could address concerns about opioid dependence and provide a differentiated product profile. Second, the company's diversification into ophthalmology through LayerBio and OcuRing-K broadens its pharmaceutical pipeline beyond a single asset, potentially reducing concentration risk over the long term.
The company's AI-driven energy business, DeepSolar, also positions PRF Technologies to participate in the growth of renewable-energy data and analytics, a segment that has drawn increasing interest as solar and battery-storage assets proliferate. For investors, PRFX represents a speculative, development-stage opportunity with exposure to both healthcare innovation and the clean-energy technology trend. Its relatively small market capitalization and early stage mean that its valuation is driven largely by clinical milestones, partnerships, and the commercialization progress of its platforms rather than by current earnings.
Investing in PRFX involves substantial risks. As a clinical-stage company, PRF Technologies depends heavily on the success of a limited number of product candidates, particularly PRF-110 and OcuRing-K. Drug development is lengthy and expensive, and there is no guarantee that any candidate will receive regulatory approval or achieve commercial success. The company also faces intense competition from larger pharmaceutical firms with greater financial resources and established distribution networks.
Financial risk is significant. The company has historically generated little revenue and reported net losses, which may require additional capital raises that could dilute existing shareholders. Its expansion into renewable-energy analytics and AI is a notable strategic shift that carries execution risk, as these are newer, less-proven areas of the business. Macroeconomic sensitivity, regulatory hurdles in both pharmaceuticals and energy, and the inherent volatility of small-cap stocks are additional factors investors should weigh carefully.
For investors seeking to research stocks and ETFs at scale, Tickeron's AI Screener is an AI-powered discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. It enables users to screen thousands of stocks and ETFs efficiently and surface ideas that match their own investment strategies, making it a practical tool for building watchlists and refining research.
PRF Technologies Ltd. is a small-cap, development-stage company whose profile has shifted from a single-product pain-reformulation specialist to a diversified platform spanning specialty pharmaceuticals, ophthalmology drug delivery, and AI-driven renewable-energy analytics. That diversification is what makes the company distinctive among early-stage issuers, but it also introduces additional complexity and execution risk. PRFX remains relevant to investors as a speculative exposure to innovation in both healthcare and clean-energy technology, best understood as a high-risk, early-stage story driven by clinical milestones and platform development rather than by current profitability.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsGeneric